Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response

BACKGROUND: This study evaluated the feasibility of achieving high response rates in stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and histopathological features and the Oncotype DX Breast Recurrence Score. Genomic determinants of response and resistance were also exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Caitlin, Muscat, Andrea, Ashley, David, Mukaro, Violet, West, Linda, Liao, Yang, Chisanga, David, Shi, Wei, Collins, Ian, Baron-Hay, Sally, Patil, Sujata, Lindeman, Geoffrey, Khasraw, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375556/
https://www.ncbi.nlm.nih.gov/pubmed/30763338
http://dx.doi.org/10.1371/journal.pone.0210891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375556/
https://www.ncbi.nlm.nih.gov/pubmed/30763338
http://dx.doi.org/10.1371/journal.pone.0210891

Ejemplares similares